Sugi Predict

Sugi Predict / Compounds / SCHEMBL306474

SCHEMBL306474

SCHEMBL306474

NC(=O)C(C(N)=O)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.48
▸ HDAC4 P56524 1/20 0.48
▸ HDAC1 Q13547 1/20 0.48
▸ HDAC7 Q8WUI4 1/20 0.48
▸ HDAC2 Q92769 1/20 0.48
▸ HDAC10 Q969S8 1/20 0.48
▸ HDAC11 Q96DB2 1/20 0.48
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ HDAC9 Q9UKV0 1/20 0.48
▸ HDAC5 Q9UQL6 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.46
▸ KCNN4 O15554 1/20 0.46
▸ IDO1 P14902 2/20 0.44
▸ TDO2 P48775 2/20 0.44
▸ CES2 O00748 1/20 0.44
▸ CES1 P23141 1/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ ALPG P10696 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351263 0.89 SRC (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4480606 0.83 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL6321555 0.81 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5114354 0.81 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL19735013 0.81 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5114349 0.81 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4092644 0.81 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3710055 0.80 SRC (0.61) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15434305 0.79 EPHX1 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL249274 0.79 HDAC3 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104302287-B Indolin-2-one derivatives as protein kinase inhibitors 安基生技新药股份有限公司 2017-12-26 — — CN claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 — — EP claimed
US-8093264-B2 Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2012-01-10 — — US claimed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 — — US claimed
CN-1553899-A Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds ������������ʽ���� 2004-12-08 — — CN claimed
CN-122036603-A Preparation method of anti-tumor drug cabatinib 新乡学院 2026-05-15 — — CN disclosed
CN-114044742-B Chiral primary amine malonamide compound and preparation method and application thereof 河北工业大学 2023-02-10 — — CN disclosed
CN-114044742-A Chiral primary amine malonamide compound and preparation method and application thereof 河北工业大学 2022-02-15 — — CN disclosed
CN-106632028-B A kind of rich preparation method for Buddhist nun of card 上海再启生物技术有限公司 2019-01-22 — — CN disclosed
CN-108503650-A Dioxane and quinazoline compounds or its pharmaceutical salts or its hydrate and its application as tyrosine kinase inhibitor 北京赛特明强医药科技有限公司 2018-09-07 — — CN disclosed
CN-104302287-B Indolin-2-one derivatives as protein kinase inhibitors 安基生技新药股份有限公司 2017-12-26 — — CN disclosed
CN-100577663-C Fused heterocyclic kinase inhibitors BRISTOL MYERS SQUIBB CO 2010-01-06 — — CN disclosed
EP-1761268-A4 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-07-08 — — EP disclosed
CN-100415720-C Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same KIRIN BREWERY (JP) 2008-09-03 — — CN disclosed
EP-1761268-A2 PYRROLOTRIAZINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-03-14 — — EP disclosed
CN-1906167-A Novel pyridine derivative and pyrimidine derivative (2) EISAI CO LTD (JP) 2007-01-31 — — CN disclosed
CN-1906166-A Novel pyridine derivative and pyrimidine derivative (1) EISAI CO LTD (JP) 2007-01-31 — — CN disclosed
WO-2006004833-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
CN-1553899-A Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds ������������ʽ���� 2004-12-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 HDAC3 1397/4885HDAC4 2230/4885HDAC1 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.